Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ToleroMune Grass in Grass Allergic Subjects
NCT01385800Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Aug 2011
- Primary completion
- Jul 2013
- Modality
- Peptides, Peptide-based Cancer Vaccines, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of grass-spire in allergic rhinoconjunctivitis (ARC), sponsored by NIOX Group. Started Aug 2011; status: completed.
02
Drugs
grass-spire
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01385800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01385800.